Merrimack Pharmaceuticals Advances Oncology Pipeline with MM-398 and MM-121
• Merrimack Pharmaceuticals is focusing on advancing its oncology pipeline, particularly MM-398 for metastatic pancreatic cancer and MM-121 for various solid tumors.
• A global phase III study of MM-398 is underway, evaluating its efficacy against 5-Fluorouracil and Leucovorin in patients who have failed Gemcitabine treatment.
• MM-121, in partnership with Sanofi, is being tested in phase II studies across non-small cell lung cancer, HER2-negative breast cancer, and platinum-resistant ovarian cancers.
• Merrimack's pipeline includes other clinical drug candidates like MM-111, MM-302, and MM-151, with plans to initiate a phase I trial for DX-929, an imaging diagnostic.
© Copyright 2025. All Rights Reserved by MedPath